The preliminary efficacy, safety, and optimal dose of the MUC16xCD3 bispecific antibody ubamatamab alone or in combination with cemiplimab-rwlc continues to be explored in patients with advanced platinum-resistant ovarian cancer in the phase 2 portion of an ongoing, first-in-human, phase 1/2 study.
Ace the Case: A 62-Year-Old Woman With a Pelvic Mass, Ascites, and an Elevated Ca-125 Level healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.